



I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as First Class Mail, in an envelope addressed to: MS Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the date shown below.

Dated: November 9, 2005

Signature: *Nabeela R. McMillian*

(Nabeela R. McMillian)

Docket No.: 30699/41065
(PATENT)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of:
Ravi Acharya et al.

Application No.: 10/527,707

Filed: March 11, 2005

Art Unit: Not Yet Assigned

For: Crystal Structure of an Angiotensin-Converting Enzyme (ACE) and Uses Thereof

Examiner: Not Yet Assigned

INFORMATION DISCLOSURE STATEMENT (IDS)

MS Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

Pursuant to 37 CFR 1.56, the attention of the Patent and Trademark Office is hereby directed to the references listed on the attached Form PTO - SB/08. It is respectfully requested that the information be expressly considered during the prosecution of this application, and that the references be made of record therein and appear among the "References Cited" on any patent to issue therefrom.

All patents and publications in the attached Form PTO - SB/08 are supplied herewith, with the exception of the U.S. Patent Document, in accordance with the waiver of the requirement under 37 CFR §1.98 (a)(2)(i).

This Information Disclosure Statement is not intended to constitute an admission that any patent, publication or other information referred to therein is "prior art" for the instant application under any section of 35 U.S.C. §102 or 35 U.S.C. §103.

In accordance with 37 CFR §1.97(g), the filing of this Information Disclosure Statement shall not be construed to mean that a search has been made or that no other material information as defined in 37 CFR §1.56(a) exists. It is submitted that the

Information Disclosure Statement is in compliance with 37 CFR §1.98 and the Examiner is respectfully requested to consider the listed references.

This Information Disclosure Statement is being filed more than three months after the U.S. filing date of the above-referenced application, but prior to the mailing date of the first Office Action on the merits (37 C.F.R. §1.97(b)). As such, no fees are believed to be necessary; however, the Commissioner is hereby authorized to charge any deficiency in the fees filed or credit any overpayments to our Deposit Account No. 13-2855. A copy of this paper is enclosed.

Dated: November 9, 2005

Respectfully submitted,

By 

Nabeela R. McMillian

Registration No.: 43,363

MARSHALL, GERSTEIN & BORUN LLP

233 S. Wacker Drive, Suite 6300

Sears Tower

Chicago, Illinois 60606-6357

(312) 474-6300

Attorney for Applicant



PTO/SB/08a/b (07-05)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Sheet	1	of	2	Application Number	10/527,707
				Filing Date	March 11, 2005
				First Named Inventor	Ravi Acharya
				Art Unit	Not Yet Assigned
				Examiner Name	Not Yet Assigned
				Attorney Docket Number	30699/41065

Complete if Known

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ² (if known)			
	A1*	US-3,832,337	08-27-1974	Ondetti et al.	
	A2*	US-3,891,616	06-24-1975	Ondetti	
	A3*	US-3,947,575	03-30-1976	Ondetti	
	A4*	US-4,052,511	10-04-1977	Cushman et al.	
	A5*	US-4,053,651	10-11-1977	Ondetti et al.	

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)				

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. * CITE NO.: Those application(s) which are marked with an asterisk (*) next to the Cite No. are not supplied (under 37 CFR 1.98(a)(2)(iii)) because that application was filed after June 30, 2003 or is available in the IFW. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	C1	Aghajari et al., Protein Sci., 11:1435-1441 (2002)	
	C2	Beldent et al., J. Biol. Chem., 268(35):26428-26434 (1993)	
	C3	Brown et al., Clin. Pharmacol. Ther., 60(1):8-13 (1996)	
	C4	Davis et al., J. Biol. Chem., 270(1):369-375 (1995)	
	C5	Devereux et al., Nucleic Acids Res., 12(1):387-395 (1984)	
	C6	Ehlers et al., Proc. Natl. Acad. Sci. USA, 86:7741-7745 (1989)	
	C7	Ehlers et al., Proc. Natl. Acad. Sci. USA, 88:1009-1013 (1991)	
	C8	Esther et al., J. Clin. Invest., 99:2375-2385 (1997)	
	C9	Hagaman et al., Proc. Natl. Acad. Sci. USA, 95:2552-2557 (1998)	
	C10	Holm et al., Nucleic Acids Res., 27(1):244-247 (1999)	
	C11	Howard et al., Mol. Cell Biol., 10(8):4294-4302 (1990)	
	C12	Huang et al., Proc. Natl. Acad. Sci. USA, 98(23):13330-13334 (2001)	
	C13	Junot et al., J. Pharmacol. Exp. Ther., 297(2):606-611 (2001)	
	C14	Kasturi et al., J. Biol. Chem., 270(24):14756-14761 (1995)	
	C15	Kumar et al., J. Biol. Chem., 264(28):16754-16758 (1989)	
	C16	Liu et al., J. Biol. Chem., 276(36):33518-33525 (2001)	
	C17	Nachon et al., Eur. J. Biochem., 269:630-637 (2002)	
	C18	Ramaraj et al., J. Clin. Invest., 102(2):371-378 (1998)	
	C19	Sadhukhan et al., J. Biol. Chem., 271(11):6429-6434 (1996)	
	C20	Simon et al., Proc. Natl. Acad. Sci. USA, 89:9367-9371 (1992)	
	C21	Trimble et al., J. Biol. Chem., 266(3):1646-1651 (1991)	
	C22	Wei et al., J. Biol. Chem., 266(14):9002-9008 (1991)	
	C23	Wheeler et al., Glycobiology, 12(4):261-271 (2002)	

Examiner Signature	Date Considered
--------------------	-----------------

Substitute for form 1449A/B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Complete if Known	
				Application Number	10/527,707
				Filing Date	March 11, 2005
				First Named Inventor	Ravi Acharya
				Art Unit	Not Yet Assigned
				Examiner Name	Not Yet Assigned
				Attorney Docket Number	30699/41065
Sheet	2	of	2		

	C24	Williams et al., J. Biol. Chem., 269(47):29430-29434 (1994)	
	C25	Yu et al., J. Biol. Chem., 272(6):3511-3519 (1997)	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--